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Summary 
The HER2 protooncogene encodes a  185-kD  transmembrane phosphoglycoprotein, human 
epidermal growth factor receptor 2 (p185u~Rz), whose amplified expression on the cell surface 
can lead to malignant transformation. Overexpression  of HER2/p185 urR2 is strongly correlated 
with progression of human ovarian and breast carcinomas. Recent studies have shown that human 
T  cells can be targeted with bispecific antibody to react  against human tumor cells in vitro. 
We have developed a bispecific F(ab')2 antibody molecule consisting of a humanized arm with 
a specificity to p185  ursz linked to another arm derived from a murine anti-CD3 monoclonal 
antibody that we have cloned from UCHT1 hybridoma. The antigen-binding loops for the anti- 
CD3 were installed in the context of human variable region framework residues, thus forming 
a fully humanized BsF(ab')2 fragment. Additional variants  were produced by replacement of 
amino acid residues located in light chain complementarity determining region 2 and heavy chain 
framework region 3 of the humanized anti-CD3 arm. Flow cytometry analysis showed that the 
bispecific F(ab')2 molecules can bind specifically to cells overexpressing p185  urR2 and to normal 
human peripheral blood mononuclear cells bearing  the  CD3  surface  marker.  In  additional 
experiments, the presence of bispecific F(ab')2 caused up to fourfold enhancement in the cytotoxic 
activities of human T cells against tumor cells overexpressing p185  n~R2 as determined by a SlCr 
release assay. These bispecific molecules have a potential use as therapeutic agents for the treatment 
of cancer. 
ecent studies have revealed an association between over- 
expression of the HER2 protooncogene and the progres- 
sion of breast and ovarian carcinomas accompanied by wor- 
sened clinical outcome (1-3).  HER2 encodes a transmem- 
brane phosphoglycoprotein receptor tyrosine kinase with an 
approximate molecular weight of 185,000 (p185  u~2) whose 
amplified expression can lead to malignant transformation 
as determined in soft agar assays and in nude mice models 
(4, 5). Thus, HER2 may play a crucial role in the tumori- 
genesis of breast and ovarian carcinomas in humans (2). Of 
relevance, cells overexpressing HER2/p185 ur~ exhibit more 
resistance  to cytotoxic effects of monocytes and TNF-ot, a 
cytokine that has direct antitumor activities  and is thought 
to mediate immune cell killing of tumor cells (5). 
1  Abbreviations used in this paler: BsmAb, bispecific mAb; FR, framework 
HER2  region;  hu, humanized; p185  , human epidermal growth factor re- 
ceptor 2. 
Bispecific mAbs (BsmAbs) with dual specificities  for tumor- 
associated antigens on tumor cells and for surface markers 
on immune effector cells have been described (6, 7). These 
BsmAbs have been shown to be effective in directing and trig- 
gering effector cells to kill tumor cell targets (8). One ap- 
proach to produce BsmAb involves the fusion of two mAb- 
producing hybridomas to form quadromas that secrete BsmAb 
in addition to undesirable chain combinations including pa- 
rental mAbs. Another approach utilizes  directed chemical 
coupling of Fab' fragments from two different mAbs to as- 
semble a BsmAb with the desired specificities (9). Limita- 
tions associated with such approaches include the ability of 
rodent-derived BsmAb to elicit immune response in humans. 
To this end, genetic engineering techniques have been ap- 
plied to production of less immunogenic "humanized" anti- 
bodies (10, 11). Recently~ we have described the humaniza- 
tion of murine mAb.4D5 (mumAb4D5), which is directed 
against the extracellular domain (ECD) of p185  ur~  The 
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antigen-binding hypervariable regions from the murine parent 
mAb together with human variable region framework residues 
and constant domains (12). 
In this report, we describe the production of humanized 
BsF(ab')2 with specificities toward the extracellular domain 
of p185  uER2, and the human T  cell  surface  marker CD3. 
Thus, one arm is humAb4D5-8 and the other a humanized 
version of murine anti-CD3 mAb, UCHT1. Our approach 
involved separate Escherichia coli secretion of each Fab' fol- 
lowed by directed chemical coupling reaction in vitro to form 
the BsF(ab')2 fragment. Data are presented demonstrating 
the biological properties  of these BsF(ab')2 molecules, in- 
cluding the specific binding to cells overexpressing p185  uER2 
and to normal human T  cells; and their ability to trigger 
the lytic activity of human CTL against breast tumor targets. 
Materials and Methods 
Cloning of  Anti-CD3 Variable  Region Genes.  The mumAb anti- 
CD3-producing  bybridoma UCHTI (13) was used for extraction 
of mR.NA (14). The genes encoding mumAb anti-CD3 variable 
domains  were isolated  by PCR amplification  of  mRNA as described 
(15). NH2-terminal sequencing of mumAb anti-CD3 light and 
heavy chains was used to design the sense strand PCR primers, 
whereas the antisense PCR primers were based upon consensus 
sequences of murine FK residues (16) incorporating unique restric- 
tion sites for directional cloning shown by underlining and listed 
after  the  sequences:  VL  sense,  5'  TTTAACGCGTACGCT- 
GACATCCAGATGACC  CAGACCACCTCCTCCCTGTCTGC- 
CTCCC~GAY3',  M/uI; VL antisense, 5' TTTGCATGCGT- 
C'ITIGGC~TAGAAGTTGTTCAAGAAGCA Y, SphI; V. sense, 
5' AACGCGTACGCTGAKGTSCAILCTSCARCARTC  3', MluI 
and V. antisense 5  ~  GGCAGAGATCCA~CCGTGGATA- 
GACAGATGG 3', A~I; where Y  =  T or C, R  =  A or G, and 
S = C. For each variable domain, the products from two indepen- 
dent PCR reactions were cloned into the pUCllg-based phagemid 
pAK2 (12), and a total of at least five  clones was sequenced  by the 
dideoxy method (17). 
Molecular Modeling and Construction of  Humanized mAb Anti-CD3 
Genes.  Humanization of mumAb anti-CD3 by installing CDK 
residues from this murine antibody into the context of consensus 
human FR sequences was performed as previously described for 
mumAb4D5-8 (12). Briefly,  mumAb anti-CD3 was humanized by 
judicious recruitment of corresponding CDR residues and a few 
FK residues into the humAb4DS-8 molecule. Differences  between 
mumAb anti-CD3 and the human consensus FR residues (see Fig. 
1) were individually  modeled to investigate  their possible  influence 
on CDR conformation and/or binding to CD3. Genes encoding 
humAb anti-CD3 variant 1 V~ and V, domains were assembled 
by gene conversion  mutagenesis  of  corresponding humAb4D5 gene 
segments cloned in pUC119 (12) using 246-met and 283-mer preas- 
sembled olignnucleotides, respectively.  Briefly,  sets of four contig- 
uous oligonucleotides were designed to create humAb anti-CD3 
V. and VL utilizing codons commonly found in highly expressed 
E. coli genes (see Fig. 1). These oligonucleotides  are 54-85 residues 
in length, contain 7-17 mismatches to the humAb4D5 templates, 
and are constrained to have  eight or nine perfectly  matched residues 
at each end to promote ef~cient annealing and ligation of adjacent 
oligonucleotides.  The sets of  oligonucleotides  were phosphoryhted, 
annealed to  corresponding templates, and  ligated.  Full-length 
oligomers were isolated after electrophoresis on a 6% acrylamide 
sequencing gel and then used for an efficient mutagenesis proce- 
dure (12). Clones precisely encoding mumAb anti-CD3 V. and 
VL (Fig. 1) were identified by nucleotide sequencing (17). 
Additional humAb anti-CD3 variants were designed in which 
one or more mumAb anti-CD3 residues were replaced by their 
human counterparts in order to test their role in antigen binding, 
namely V. K73D and/or VL R53S (a single letter code for the 
original amino acid followed by the residue number according to 
Kabbat et al. [16] and then the amino acid replacement). The mu- 
rine V. residue, K73, is located in a loop that is close to heavy 
chain CDILs H1 and H2 (Fig. 2), and might be involved  in antigen 
binding. In contrast, our humAbs usually contain an aspartate at 
this position as they are derived from a consensus sequence of V, 
group III, which is the most abundant human group in the compi- 
lation of Kabat et al. (16). V~ residue 53 is an arginine in mumAb- 
antiCD3 that is located towards the COOH terminus of CDR 
L2 and may be able to reach up and assist in antigen binding while 
also interacting with the phenyl ring of V~ Y50 (see Fig. 2). In 
our humAbs, this residue is normally a serine derived from a con- 
sensus sequence of V~ g subgroup I, which is the most abundant 
human light chain subgroup (16). These additional variants were 
generated  by an ef~cient  site-directed  mutagenesis  method (18) using 
the oligonucleotides: 
VL R53S 
5' CTATACCTCCAGCCTCGAGTCTAGGAG 3' 
XhoI 
V. K73D 
5' AAGCGTAGATGACTCCAAAAACACAGCCTACCTGCAAAT 
GAA  T I"CTCTGCGTC~TG  Y 
EcoRI 
where an asterisk indicates a mismatch and unique restriction sites 
introduced are underlined. 
Fa~ Fragment Expression for humAb4D5-8  and Anti-CD3  raAb 
Variants.  We previously described the  vector, pAK19, for the 
cosecretion of humAb4D5 light chain and heavy  chain Fd' frag- 
ments from E. coli (19), which is available upon request to the 
authors. Briefly, the Fab' expression unit is dicistronic with both 
chains under the transcriptional  control of theph0A promoter (20), 
ends with the bacteriophage X to transcriptional terminator (21) 
and is cloned between the EcoR/and HindlIl site of  pBR322 (22). 
The humanized VL and V. domains (12) are precisely fused on 
their 5' ends to a gene segment encoding the heat-stable  enterotoxin 
II signal sequence (23) and on their 3' side to human ~1 (C0 (24) 
and IgG1 (C.1) (25), followed by the hinge sequence CysAlaAla 
(19) constant domains, respectively.  Chimeric and humanized ver- 
sions of mumAb anti-CD3  Fab' were constructed by precisely 
replacing gene segments encoding humAb4D5-8 VL and V. in 
pAK19 with appropriate genes encoding mAb anti-CD3 VL and 
V. variants by subdoning (26) and site-directed  mutageuesis  as de- 
scribed (12). Fab' fragments were expressed in a phage-resistant 
derivative of E. coli strain KV308 (27) at high cell density in the 
fermentor as previously described (19). 
Constrac~n of Bispecific F(a~/)2 Fragments.  Intact and function- 
ary active humAb45D5-8 Fab' has been recovered from E. coli fer- 
mentation pastes with the unpaired hinge cysteine  present mainly 
(75-90%)  in  the  labile-free thiol  form  (Fab'-SH) by  affinity 
purification using Streptococcal protein G at pH '~5 in the pres- 
ence of 10 mM EDTA (19). The anti-CD3 mAb Fab'-SH was re- 
covered by similar procedures and reacted with 5,5'-dithiobis (2- 
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derivative (Fab'-TNB). The construction of bispecific (Bs) F(ab')2 
fragments was completed by directed chemical coupling (29) of 
Fab'-TNB derivative  of the anti-CD3 mAb with humAb4D5-8 Fab'- 
SH. Equimolar quantities of Fab'-TNB (by TNB content) and Pab'- 
SH (by SH content) were coupled at a combined concentration 
of ~>0.25 mg/ml in the presence of 100 mM Tris-HC1, pH 7.5, 
and 10 mM EDTA for 1 h at 37~  The resulting BsF(ab')2 frag- 
ments were isolated from the coupling reaction by S100-HK gel 
filtration (Pharmada Fine Chemicals, Piscataway,  NJ) in the pres- 
ence of PBS. The BsF(ab')2 samples were passed through a sterile 
0.2-/xm filter and stored either at 4~  or flash frozen in liquid 
nitrogen and stored at  -70~  until used. 
Cell Lines.  Breast  tumor cell lines SK-BK-3 and MDA-MB- 
175 were purchased from the American Type Culture Collection 
(Kockville,  MD). NK6/10 cells (NIH 3T3 fibrobhsts overexpressing 
p185  ~r~2) were obtained  from  Dr.  D.  Slamon, University  of 
California (Los Angeles, CA). With the exception of MDA-MB- 
175, these cell lines overexpress HER2/p185 uea2 as reported (3). 
The cells were grown in an equal mixture of DME and F12 Ham 
(Gibco Laboratories, Grand Island, NY) supplemented with 10% 
heat-inactivated (30 min, 56~  FCS, 2 mM L-glutamine,  100 U/ml 
penicillin, and 100 #g/ml Streptomycin  (Gibco Laboratories)  (com- 
plete medium). 
Human Cytotoxic  Lymphocytes.  Blood  of normal volunteers was 
drawn into heparinized syringes, mixed with an equal volume of 
PBS layered  onto Ficoll/Hypaque gradient (specific  gravity 1.077) 
and centrifuged for 45 min at 400 g. The separated  band of PBMC 
was aspirated, washed three times in ice cold PBS, and resuspended 
in complete medium. PBMC were depleted of monocytes by ad- 
herence to plastic  for 60 min in 100 x 60-ram plates (Costar Corp., 
Cambridge, MA) at 37~  CO2. Nonadherent PBMC were 
activated by incubation in the presence of 11.,2 for 24 h and were 
used as effector CTL against SlCr-labeled tumor targets in a 4-h 
StCr release cytotoxicity assay (30). In some experiments, effector 
CTLs were tested against targets prepared by PHA blastogenic  stim- 
ulation of PBMC obtained from the same donor of effector calls 
as detailed previously (30). 
Cytotoxicity Assay.  SK-BR-3, or NR6/10 cells (3  x  106/ml), 
were labeled with  150  #Ci of NazSlCrO4 (Amersham Corp., 
Arlington Heights, IL) for 60 min, washed, adjusted to 104 cells/ 
50 #1 of complete medium, and dispensed into round-bottomed 
microtiter plates containing quadruplicates of various numbers of 
effector CTLs in 100 #1 of complete medium. Various concentra- 
tions of Bs F(ab')2 fragments alone or mixed with p185  m~ ECD 
were then added in 50-#1 volumes (final volume per well =  200 
/~1) and the plates were incubated at 37~  CO2. After 4 h, 
the supernatants were harvested (Skatron Inc., Sterling, VA), and 
their radioactivity  was determined using a gamma counter (Micro- 
medic Systems, Inc., Horsham, PA). Percent cytotoxicity was cal- 
culated as follows: percent cytotoxicity =  100x (A -  B)/(C  - 
B); where A represents the mean counts per minute (cpm) in test 
supernatants, B represents the mean cpm in supernatants of targets 
alone (spontaneous S~Cr release), and C represents the mean cpm 
in supernatants of targets lysed with 1% SDS (maximum SlCr 
release). 
Flow Cytometric Analysis of BsF(ab')2 Binding.  Aliquots of 106 
cells were mixed in either PBS  +  1% FCS (PBS +  1%) or PBS 
+  1% containing chimeric or humanized BsF(ab')2 (10 #g/ml). 
The cells were incubated on ice for 45 rain, washed twice in PBS 
+  1%, and stained with fluorescein-labeled  goat anti-human Fab 
(Tago Inc., Burlingame, CA) for 45 min. In experiments involving 
the blocking of BsF(ab')2 binding, cells were treated with BsF(ab')2 
antibody in the absence or presence of soluble p185  sea2 extracel- 
lular domain preparation of the p185  n~e2, or rCD4 receptor as a 
negative  control (50 #g/ml) before  addition of  the fluorescein-hbded 
reagent. The stained cells were washed four times in ice-cold PBS 
+  1% and analyzed using a FACS  |  (Becton Dickinson & Co., 
Mountain View, CA). 10  s cells were acquired by list mode, and 
measurements were performed on a single-cell  basis and were dis- 
played as frequency  distribution histograms. Dead cells and debris 
were gated out of the analysis  on the basis of forward light scatter. 
Results 
Humanization of mumAb Anti-CD3 V~ and Vs.  The gene 
segments encoding mumAb anti-CD3 V~ and V, were first 
cloned by PCR from the corresponding hybridoma, UCHTI, 
and sequenced  (Fig.  1). Next, the deduced variable domain 
amino acid sequences and molecular modeling were used to 
design a humanized variant of mumAb anti-CD3 (vl) (Fig. 
2) as previously described for mumAb4D5 (12). Corresponding 
genes for humanized anti-CD3 vl were created by gene con- 
version mutagenesis (12) starting from humAb4D5 genes and 
using long preassembled oligonucleotides (Fig. 1). As detailed 
in Materials and Methods, further humanized anti-CD3 vari- 
ants were created by replacement of two additional residues 
from mumAb anti-CD3 with their human counterparts to 
investigate their role in antigen binding. Thus, humanized 
anti-CD3 v2 and v3 incorporate the replacements  V. K73D 
and VL R53S, respectively, whereas v4 includes both of these 
changes. 
Preparation of BsF(at02 Fragments.  We have previously de- 
scribed the secretion of  functional humAb4D5 Fab' fragments 
from E. coli  at titers of 1-2 g/liter as  judged by antigen-binding 
ELISA after affinity purification on Staphylococcal  protein 
A (19). Chimeric and humanized versions of anti-CD3 were 
expressed in the same vector (pAK19) at titers of up to 400 
mg/liter as judged by total Ig ELISA. Fab' fragments were 
recovered from E. coli cell pastes with the hinge cysteine present 
mainly (75-90%) as the free thiol (Fab'-SH). This was achieved 
by affinity  purification of  Fab'-SH on Streptococcal protein G 
at pH 5 to maintain the thiol in the less reactive protonated 
form and in the presence of EDTA to chehte metal ions capable 
of catalyzing disulfide bond formation. Bs F(ab')2 fragments 
were then constructed by directed chemical coupling in vitro 
of humAb4D5 Fab' and anti-CD3 mAb Fab' using the pro- 
cedure of Brennan et al. (29). One arm of the BsF(ab')2 was 
always  the most potent humanized anti-p185 ur~z variant 
previously identified (humAb4DS-8), which binds p185  ur-~2 
ECD threefold more tightly than the murine parent Ab (12). 
The other arm was either a chimeric or humanized variant 
of the anti-CD3 mAb. Henceforth in this text the term chi- 
meric BsF(ab')2 refers to a molectfle in which one arm is the 
humanized anti-p185 ue~ and the other arm is the chimeric 
anti-CD3;  and the terms BsF(ab')2 vl, v2, v3, and v4 de- 
scribe  a  molecule in  which  one  arm  is  humanized anti- 
p185  HEa2 and the other arm is humanized anti-CD3 variant 
1,  2,  3,  and 4,  respectively  (Fig.  2). 
Specific Binding of BsF(aP)2 Fragments to Cells.  Binding of 
BsP(ab')2 fragments to NRr/10 cells overexpressing HER2/ 
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muMAb anti-CD3 V L  10  2 0  3 0  4 0 
ga  C  a  t  c  c  ag  a  t  ga  c  c  c  aga  c  c  a  c  c  t  c  c  t  c  c  c  t  gt  C  t  g  c  c  t  c  c  c  t  gggcga cAGAGTCACCATCAGTTGCAGGGCAAGTCAGGACAT  TAGAAAT TAT  T  TAAACTGGTATCAACAGAAACCAGAT 
D  I  Q  M  T  Q  T  T  S  S  L  S  A  S  L  G  D  R  V  T  I  S  C  R  A  S  Q  D  I  R  N  Y  L  N  W  Y  Q  Q  K  P  D 
*  *  *  *  CDR-LI  * 
D  I  Q  M  T  Q  S  P  S  S  L  S  A  $  V  G  D  R  V  T  I  T  C  R  A  S  Q  D  I  R  N  Y  L  N  W  Y  Q  Q  K  P  G 
GATATCCAGATGACCCAGTCCCCGAGC  TCCC  TGTCCGCCTCTGTGGGCGATAGGGTCACCACTACC  TGCCGTC-CCAGTCAGGACATCCGTAATTATC  TGAACTGGTATCAACAGAAACCAGGA 
<--  -><- 
huMAb  anti-CD3  variant 1 VL 
50  60  70  80 
GGAAC TGTTAAAC T  CCTGATC T  ACTACACATCAAGATTACACTCAGGAGTCCCATCAAAGT  TCAGTGGCAGTGGGTCTGGAACAGAT  TAT  TCTCTCACCATTAGCAACC  TGGAGCAAGAGGAT 
G  T  v  K  L  L  I  Y  Y  T  S  R  L  H  S  G  V  P  S  K  F  S  G  S  G  S  G  T  D  Y  S  L  T  I  S  N  L  E  Q  E  D 
*  *  *  CDR-L2  #  *  *  *  *  *  * 
K  A  P  K  L  L  I  Y  Y  T  S  R  L  E  S  G  V  P  S  R  F  S  G  S  G  S  G  T  D  Y  T  L  T  I  S  S  L  Q  P  E  D 
AAAGC TCCGAAACTAC  TGAT  TTAC  TATACCTCCCGCCTGGAGTC  TGGAGTCCCTTC  T  CGC  T  TC  TCTGGTTCTGGT  TC  TGGGACGGATTACAC  TC  TGACCATCAGCAGTCTGCAACCGGAAGAC 
--><- 
90  10C 
ATT~CACTTACTTTT~C~CAG~T~TACGCTTCCGT~ACGTTC~TGGA~CACC~T~AAATCAAACGGGCT 
IATYFCQQGNTLPWTFAGGTKLEIKRA 
*  *  CDR-L3  *  *  *  * 
FATYYCQQGNTLPWTFGQGTKVEIKRT 
TTCGC~CTTATTACTGTCA~GGT~TACTCTGCCGT~ACGTTC~ACAGGGCACC~GGTGGAGATCAAACG~CT 
_><_  -> 
B 
muMAb anti-CD3 VH  i0  20  30  40 
g  a  gg  t  g  c  a  g  c  t  c  c  a  g  c  a  g  t  c  T  G  G  ACC  T  GAG  CT  GGT  GAAGCC T  GGAC-C  T  T  CAAT  GAAGAT AT  CC  T  GCAAGGC T  T  C  T  G  GT  T  ACT  CAT  T  C  ACT  G  GCTACACCATGAACTGGGT  GAAGC  AGAGT  CAT 
E  V  Q  L  Q  Q  S  G  P  E  L  V  K  P  G  A  S  M  K  I  S  C  K  A  S  G  Y  S  F  T  G  Y  T  M  N  W  V  K  Q  S  H 
*  ￿9  *  *  .  .  *  *  *  ~  *  *  . 
E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G  G  S  L  R  L  S  C  A  A  S  G  Y  S  F  T  G  Y  T  M  N  W  V  R  Q  A  P 
G  AGGT  TCAGCTGGTGGAGTCTGGCGGT  G  GCCTGGTGCAGCCAGGGGGC  TCACTCCGTT TGTCCTGTGCAGC  TTC  TGGC  TACT  CC  TT  TACCGGCTACACTATGAAC  TGGGTGCGTCAGGCCCCA 
<- 
huMAb  anti-CD3  variant 1 Vn 
50  a  60  70  80 
G  GAAAGAACCT TGAGTGGATGGGACT  TATTAATCCT TACAAAGGTGT  TAGTACCTACAACCAGAAGTTCAAGGACAAGGCCACAT  T  C  ACTGTAGACAAGTCAT  C  CAGCACAGCCTACATGGAA 
G  K  N  L  E  W  M  G  L  I  N  P  Y  K  G  V  S  T  Y  N  Q  K  F  K  D  K  A  T  L  T  V  D  K  S  S  S  T  A  Y  M  E 
*  *  *  CDR-H2  *  *  *  *  *  *  *  *  *  *  #  *  *  * 
G  K  G  L  E  W  V  A  L  I  N  P  Y  K  G  V  T  T  Y  A  D  S  v  K  G  R  F  T  I  S  V  D  K  S  K  N  T  A  Y  L  Q 
G  GT  AAGGGCCTGGAAT  G  GGT  TGCAC  TGATTAAT CCT  TATAAAGGTGTTAC  TACCTATGCCGATAGCGTCAAGGGCCGT  TTCAC  T  ATAAGC GTAGATAAATCCAAAAACACAGCC  TACCTGCAA 
_><_  --><-- 
a  b  c  90  i00  ii0 
C  T  CC  TC  A  GTC  TGACATCTGAGGAC  TC  TGCAGT C  TAT  TAC  TGTGCAAGATCGGGGTACTACGG  TGATAGTGAC T  GGTACT T  CGATGTC T  GGGGCGCAGGGACCACGGTCACCGT  C  TCCTCA 
L  L  S  L  T  S  E  D  S  A  V  Y  Y  C  A  R  S  G  Y  Y  G  D  S  D  W  Y  F  D  V  W  G  A  G  T  T  V  T  V  $  S 
.  *  *  *  *  CDR-H3  *  * 
M  N  S  L  R  A  E  D  T  A  V  Y  Y  C  A  R  S  G  Y  Y  G  D  S  D  W  Y  F  D  V  W  G  Q  G  T  L  V  T  V  S  S 
AT  G  AACAGCC TGCGTGCTGAGGACAC  TGCCGTCTAT TATTGTGCTAGAAGCGGAT  A  CTACGGCGATGACGAC  TGGTAT T  T  T  G  AC  GTC  TGGGGTCAAGGAACCCT  G  GTCACCGTC TCC  T  CG 
_><_  --> 
Figure 1.  Amino acid and nucleotide sequences of mumAb anti-CD3 and humAb anti-CD3 variant 1 Vt (A) and V. (B). Amino acids are num- 
bered using the scheme of Kabat et al. (16) to accommodate differences in V domain lengths.  For example, the residues between V, positions 82 and 
83 are designated 82a, 82b, and 82c, respectively. The 5' end of mumAb anti-CD3 Vt and V. nucleotide sequences are derived from the corresponding 
PCR primers and are identified by lower case (see Materials and Methods).  Amino acid sequence differences between mumAb and humAb anti-CD3 
are shown by asterisks, and residues that were replaced in generating additional humanized variants are indicated by pound signs (see text). The CDR 
residues according to sequence (16) and structural (38) definitions are shown by overlining and underlining of the CDR label, respectively. Genes en- 
coding humAb anti-CD3 V~ and V. variant 1 were created by gene conversion mutagenesis  (12) of corresponding mumAb4D5 genes using sets of 
four contiguous oligonucleotides  whose 5' and 3' ends are shown by arrows below the sequences (see Materials and Methods). 
p185 u~R2 was investigated by flow cytometric  analysis (Fig. 
3). Chimeric BsF(ab')2 significantly bound to NR6/10  cells 
as shown by a significant increase in the fluorescence inten- 
sity compared with background level (A and B). The pres- 
ence  of p185 u~R2 ECD  (50  /~g/ml)  in  the  binding  assay 
reduced the binding of chimeric BsF(ab')2  almost to back- 
ground level (C),  whereas addition of an irrelevant  soluble 
receptor (rCD4) at a similar concentration did not interfere 
with the binding (D). These results demonstrate the specificity 
of  chimeric  BsF(ab')2  binding  to  cells  overexpressing 
p185 urR2.  Similar  results  were  obtained  using  BsF(ab')2 
vl-v4. 
Additional FACS  |  experiments were performed to quan- 
tify the binding of BsF(ab')2 fragments to human CTLs and 
to  breast  tumor  SK-BR-3  cells.  All  Bs  F(ab')2  fragments 
bound to SK-BR-3 cells with equal efficiency as anticipated 
since the anti-p185 HE~ arm is identical in these molecules 
(Fig. 4, left). In contrast,  there were significant differences 
in the binding efficiency of these molecules to human CTLs. 
Chimeric BsF(ab')2  antibody was most effective in binding 
(Fig. 4, right, B) followed by BsF(ab')2 vl (C), v3 (E), and 
v2 (D), as reflected by different peaks of fluorescence intensi- 
ties;  BsF(ab')2 v4 antibody was least effective in its binding 
to cytotoxic lymphocytes (F). Thus, the manipulation of the 
anti-CD3 arm of the BsF(ab')2 fragments profoundly altered 
its binding to lymphocytes. 
Targeting of Tumor Cell  Killing  by BsF(ab')2 Fragments. 
The killing of cells overexpressing  p185 hER2 (NR6/10)  or 
breast tumor cells SK-BR-3 by activated human cytotoxic lym- 
phocytes was examined in the presence of various doses of 
BsF(ab')z,  and preliminary results indicated that as little as 
10 ng/ml of chimeric BsF(ab')z or BsF(ab')z vl was sufficient 
to cause maximal enhancement in the cytotoxic  activity of 
CTLs. This dose (10 ng/ml) was used to compare the ability 
220  Targeted  Tumor Killing With Bispecific Antibodies Figure 2.  Stereoview  of  humanized anti-CD3 Variant 1 
VL and Vx domains. An or-carbon trace is shown with 
side chains of  residues  that differ  between  the murine and 
humanized versions. The six CDKs are labeled, and the 
side chains of VL K53 and V. K73 are represented by 
space-filling balls. 
of chimeric  BsF(ab')2  to  enhance  the  cytotoxic activity of 
CTL with each of the BsF(ab')2  variant molecules. The ad- 
dition  of 10 ng/ml  of chimeric  BsF(ab')z,  BsF(ab')2  vl,  or 
v3 caused a three- to fourfold enhancement  of the cytotox- 
icity of CTLs against SK-BR-3 breast tumor cells (Fig.  5 A) 
whereas the presence of BsF(ab')2 v2 or v4 resulted in no en- 
hancement  above control  values.  Enhancement  caused by 
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Figure  3.  Flow cytometric 
analysis of  NR6/10 cells  bound  to 
chimeric BsF(ab')2. Cells were in- 
cubated with PBS (A), chimeric 
BsF(ab')2 (B), chimeric BsF(ab')2 
mixed with p185  usR2 ECD (C), 
or chimeric BsF(ab')2  mixed with 
recombinant  CD4  (D)  before 
staining with goat anti-human 
F(ab')2-FITC (conjugated Ab). 
BsF(ab')2 vl was reversed by the addition of p185  usR2 ECD 
to the assay mixture (Fig. 5 A) demonstrating the specificity 
of antibody action. The results from an independent experi- 
ment (Fig.  5 B) demonstrate that  10 ng/ml  of BsF(ab')2  vl 
consistently enhanced the function of CTLs against SK-BR- 
3 targets known to overexpress  p185 HrPa (64 pg//~g cell pro- 
tein;  3,  12) but had no effect on the cytotoxicity of CTLs 
against MDA-MB-175 targets,  which express low to moderate 
levels  of p185  urR2 (7.7  pg//~g  cell protein;  3,  12).  These 
results demonstrate the efficacy of chimeric BsF(ab')2 vl, and 
v3 in directing cytotoxic lymphocytes to kill breast  tumor 
targets  overexpressing  p185  u~R2 but  not  targets  with  low 
p185  HrR2 expression. The cytotoxicity data (Fig.  5 A) corre- 
late well with FACS  |  binding data (Fig.  4) in that BsF(ab')2 
v2  and v4,  which were inefficient  in binding  to cytotoxic 
lymphocytes, failed to direct tumor cell killing in the cyto- 
toxicity assay. None of these BsF(ab')2 molecules affected the 
cytotoxic activity of human CTL when tested against PHAo 
induced  blastogenic  targets  derived from  the  same donor, 
demonstrating  that these BsF(ab')z do not mediate the lysis 
of normal  autologous  lymphoid cells. 
Discussion 
Considerable progress has been made toward the develop- 
ment  of BsmAbs as  therapeutic  agents  for  human  cancer 
(reviewed in reference 9). Human CTLs directed with BsmAb 
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Figure  4.  Flow cytometric  analysis of the binding of BsF(ab')z anti- 
bodies to human CTLs and human breast tumor SK-BR-3  cells.  Histo- 
grams  on the left illustrate SK-BR-3  cells incubated with PBS (A), chi- 
meric BsF(ab')2 (B), Bsr(ab')2 vl (C), v2 (D), v3 (E), or v4 (F) before 
staining with the FITC-conjugated  Ab. Histograms on the right illustrate 
human CTLs incubated with PBS (A), chimeric BsF(ab')z (B), BsF(ab')2 
vl (C), v2 (19), v3 (E), or v4 (F) before staining with FITC conjugated Ab. 
have been shown to block the growth of human tumor xeno- 
graphs in nude mice (31, 32). In other studies involving car- 
cinoma patients, local lysis of tumor cells was observed after 
infusion of T cells activated with BsmAb (8).  In addition, 
the efficacy of antitumor associated antigen  x  anti-CD3- 
bispecific antibody in the management of malignant glioma 
has been reported (33). A major drawback for the applica- 
tion of murine mAbs has been the elicitation of an immune 
response after repeated administration into humans. The hu- 
manization of BsmAb may reduce the immunogenicity of 
these reagents,  thus avoiding possible  untoward effects  in 
human subjects  (10,  11, 34). 
The development of biologically active fully humanized 
BsF(ab~  fragments as demonstrated  in this study has not 
been reported previously.  We have used an efficient  E.  coli 
expression system (19) for the production of humanized lab' 
molecules  with  anti-p185 urRz and  anti-CD3  specificities. 
The Fab' molecules were recovered with the unpaired hinge 
cysteine  present  as  the  free thiol  and  used  to  form  the 
BsF(ab')z by directed chemical coupling in vitro (29).  The 
approaches used in this study obviate the inherent problems 
in generating Fab'-SH from intact antibodies:  differences in 
susceptibility to proteolysis and nonslx~ific cleavage resulting 
in heterogeneity,  low yield, as well as partial reduction that 
is not completely selective for the hinge disulfide bonds (29). 
Furthermore, by engineering the hinge region to leave a single 
cysteine  residue,  we prevent  intrahinge disulfide  bonding 
without resorting to the use of highly toxic arsenite to che- 
late vicinal thiols (29). The purified BsF(ab')2 antibody frag- 
ments are reactive with human T cells and cells overexpressing 
p185  u~2. The ability of these BsF(ab')2 to mediate targeted 
killing of tumor cells  correlated well with their  efficiency 
of binding to CTLs as revealed by FACS  |  analysis. 
The humanization of the anti-CD3 arm (as in vl) resulted 
in a decrease in the binding efficiency to CTL but did not 
alter the ability of the molecule to enhance CTL cytotoxicity 
against tumor targets at the lowest BsF(ab')z concentration 
studied (10 ng/ml).  The observation  that <2% occupancy 
by antibody is sufficient to trigger T cell activation (35) to- 
gether with the high degree of purity of the BsF(ab')~ used 
may explain the observed potency of the humanized version 
in mediating tumor cell killing at pharmacological  concen- 
trations  (10 ng/ml). 
Replacement of the murine residue Vc R53 with serine 
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Figure 5.  Targeting of breast tumor 
cell killing by BsF(ab')z. 5tCr-labeled 
SK-BR-3 targets (7") were co-incubated 
with effector (E) CTLs at different E/T 
ratios for 4 h. In A, percent cytotox- 
icity was calculated based on SlCr re- 
lease in cultures with no antibody ~_dd~ 
(&), in the pzesence of 10 ng/ml of chi- 
meric BsF(ab')z (O), BsF(ab')a vt (O), 
v2  (O),  v3  (I),  v4  (A),  or vl  + 
p185uUR2ECD  ([]).  In  B,  two 
different slCr-labeled  target cells were 
used.  MDA-MB-175  targets  tested  in 
the absence (O) or presence (e) of 10 
ng/ml of BsF(ab')z vl; and SK-BK-3 
targets tested in the absence ([]) or pres- 
ence (A) of 10 ng/ml of BsF(ab')2 vl. 
The MDA-MB-175 cells ~press low to 
moderate levd of p185  uF-~ as quantita- 
tively stated in Results. (human residue) in humanized anti-CD3  vl  to create  v3 
resulted in little or no change in the binding efficiency to 
CTL, suggesting that VL R53 is probably not an essential 
antigen-binding determinant. The binding efficiency of vl, 
however, was severely reduced upon the replacement of V, 
K73 with the human counterpart, Asp, in FR3 to make v2. 
Further reduction of the binding to CTLs was observed when 
V~ R53 in v2 was replaced by Ser to create v4, whose bind- 
ing capacity to CTLs was almost completely abolished. Given 
the fact that VH K73 is outside of the CDRs, these results 
imply that contact between selected amino acid residues in 
FRs with other residues in adjacent CDRs or direct interac- 
tion with antigen can influence the antigen-binding efficiency 
and specificity of the hypervariable loops (11, 36). However, 
additional amino acid replacements are required to determine 
whether murine residue V. K73 is an important binding de- 
terminant or whether the human residue D73 compromises 
binding. Nevertheless, these data demonstrate that amino acid 
residues outside CDRs should be considered in mAb humani- 
zation. Additional amino acid replacements are currently being 
installed in the humanized anti-CD3 Fab' in an effort to im- 
prove its binding efficiency. A three-dimensional molecular 
model of the humanized (vl) anti-CD3 arm VL and V~ do- 
mains is presented (Fig.  2),  illustrating the side chains  of 
residues that differ between murine and humanized versions 
of anti-CD3 arm. This figure shows that V. K73 in FR3 
is located in a loop proximal to CDRs H1 and H2. 
The fact that a number of adenocarcinomas are character- 
ized by an overexpression of p185  u~R2 presents a unique op- 
portunity for testing the feasibility as well as the efficacy of 
targeted tumor immunotherapy whereby patients CTLs can 
be redirected with BsmAb for tumor killing. Fully humanized 
BsF(ab')2 fragments are shown here to be effective mediators 
of human breast tumor target lysis in vitro at pharmacologi- 
cally relevant concentrations. We are currently investigating 
whether these molecules may be capable of targeting breast 
tumor cells in vivo for destruction by CTLs. The fact that 
these molecules are fully humanized and, therefore, less likely 
to elicit an immune response in cancer patients further ad- 
vances their potential use in targeted immunotherapy. Im- 
portantly,  the  BsF(ab')2  molecules failed  to  mediate  the 
killing of normal lymphoid cells (PHA-blasts) or even tumor 
cells expressing only low to moderate levels of p185  uEaz. 
The mechanism(s) by which CTLs cause the lysis of tumor 
targets are not known. However,  it has been reported that 
the cytolytic activity is induced by the binding of antibody- 
target conjugates to specific receptors on the effector cell sur- 
face (6). One view proposes that the crosslinking by BsmAbs 
between clusters of receptors on tumor targets and triggering 
structures on immune effector cells can induce the release of 
effector cytolytic substances including cytolysin which may 
contribute to target killing (8). Crosslinking may also acti- 
vate T  cells for production of cytokines, e.g., TNF-o~ and 
IFN-% both of which can exert cytotoxic effects on tumor 
cells in vitro. The data in this report are consistent with the 
crucial requirement for crosslinking in order to trigger effector 
killing of tumor target. Thus two of the BsF(ab')2 variants, 
v2 and v4, shown to be perfectly capable of binding to target 
cells but not to effector CTLs, failed to direct tumor killing 
in the cytotoxicity assay. Further, the presence of p185  uraz 
ECD,  which is  shown to block BsF(ab')2 binding to the 
target, caused a marked inhibition of directed CTL killing 
of tumor targets. 
Our E. coli Fab' expression  system in combination with 
directed chemical coupling as described here has proven effec- 
tive in the production of clinically relevant quantities of ~nc- 
tional humanized antibody fragments. The availability  of 
purified material should facilitate  the imtiation of clinical 
studies to evaluate the efficacy of BsF(ab')2 in redirecting 
CTL killing of tumor cells. It should be noted that the use 
of F(ab')2 fragments should permit for a more efficient tissue 
penetration in vivo (37). The systems used here also allow 
for replacements of amino acid residues in CDRs and FRs 
making it possible to study structure-function relationships 
among the different variant Ab fragments. 
Collectively, the data presented here demonstrate the feasi- 
bility of producing genetically engineered fi~lly humanized 
BsF(ab')2 shown to be biologically active in two different in 
vitro assays. The expression systems described can be applied 
efficiently for the production of Fab' molecules with selected 
specificities, and offer an opportunity for understanding the 
structure-function relationship among the produced Ab frag- 
ments. These and similar studies will advance the potential 
use of BsmAbs in  targeted immunotherapy of cancer  in 
humans. 
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